Investors & Media
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
Please use the Investor & Media drop down menu to access more tools and information
- Merus to Participate in Guggenheim Healthcare Talks Idea Forum
- Merus Announces IND Clearance for MCLA-145
- Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
- Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update
- Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals